Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entelon 50mg in Non-Proliferative Diabetic Retinopathy
NCT05358080Phase 4Unknown
- Sponsor
- Hanlim Pharm
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial comparing Entelon 50mg with Placebo (2 arms). Primary endpoint: Proportion of subjects maintained or improved in DRSS level at 24 months. Status: unknown.
02
Drugs
vitis vinifera extract
Beyond the preview
Go deeper on NCT05358080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358080.